Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review
<p>Abstract</p> <p>Background</p> <p>Cancer and its therapies increase the risk of venous thromboembolism. Compared to patients without cancer, patients with cancer anticoagulated for venous thromboembolism are more likely to develop recurrent thrombotic events and majo...
Main Authors: | Sperati Francesca, Terrenato Irene, Rohilla Sandeep, Barba Maddalena, Akl Elie A, Muti Paola, Schünemann Holger J |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-07-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Online Access: | http://www.jeccr.com/content/27/1/21 |
Similar Items
-
Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism
by: Isabel Elías, et al.
Published: (2016-05-01) -
Low-molecular-weight heparins in the treatment of venous thromboembolism
by: Huisman Menno V, et al.
Published: (2000-08-01) -
Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
by: Patel R
Published: (2016-05-01) -
Why differentiate low molecular weight heparins for venous thromboembolism?
by: Walenga Jeanine M, et al.
Published: (2007-06-01) -
An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation
by: Akl Elie A, et al.
Published: (2010-03-01)